The combination of tislelizumab and chemotherapy produced sustained and clinically meaningful survival benefits with manageable toxicity among patients ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and ...

A team led by Professor Inkyung Jung from the Department of Biological Sciences at KAIST, working with Professor Yarui Diao’s ...

Financing Expected to Fund Completion of Phase 2 Ovarian Cancer TrialFinancing Supports Acceleration Toward Pivotal Trial and CommercializationFinancing Structured ...

Researchers at Fred Hutch Cancer Center are testing whether a collaborative AI research platform can accelerate the pace of ...

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small-cell lung cancer will benefit from immunotherapy.

Breast cancer remains one of the most prevalent and life-threatening forms of cancer, impacting millions worldwide. This malignancy's heterogeneity and complexity have long posed significant ...

Akeso, Inc. (9926.HK) ("Akeso"), and INOVIO (NASDAQ: INO) today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate cadonilimab, Akeso's ...

Dedifferentiated liposarcoma lacks effective IGF-1→PPAR-γ adipogenic signaling due to epigenetic silencing of PPAR-γ2, with ...

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') announced that the latest long-term survival analysis data from the China ...

Collaboration will evaluate INOVIO's INO-5412 (INO-5401 plus INO-9012) in combination with Akeso's cadonilimab as a potential treatment for glioblastoma (GBM), the most common and aggressive ...

Editor’s note: This round‑up is based on press releases, peer‑reviewed publications, and company communications received in January and February 2026. All results are preliminary unless stated, and ...